SCHEMBL14280736

SCHEMBL14280736

CC(C(=O)O)c1cccc(Oc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.69
MEN1 O00255 1/20 0.52
CYP2D6 P10635 1/20 0.52
KMT2A Q03164 1/20 0.52
AKR1C3 P42330 6/20 0.52
AKR1C2 P52895 6/20 0.52
AKR1C4 P17516 1/20 0.49
AKR1C1 Q04828 1/20 0.49
PPARG P37231 3/20 0.45
MAPT P10636 2/20 0.44
CXCR1 P25024 2/20 0.44
CXCR2 P25025 2/20 0.44
PTGS2 P35354 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RECQL P46063 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
R-Fenoprofen SCHEMBL4082 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL8754928 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
R-Fenoprofen SCHEMBL30910976 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL11336376 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL3797 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL29481372 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
(S)-Fenoprofen SCHEMBL4492279 0.82 PTGS1 (1.00) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL4081 0.81 PTGS1 (0.97) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL11125651 0.81 PTGS1 (0.97) PTGS1MEN1CYP2D6KMT2AAKR1C3
Fenoprofen SCHEMBL8706502 0.81 PTGS1 (0.97) PTGS1MEN1CYP2D6KMT2AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021085-A1 METHOD OF REDUCING ABETA42 AND TREATING DISEASES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2008-01-24 US disclosed
US-20080021085-A1 METHOD OF REDUCING ABETA42 AND TREATING DISEASES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021085-A1 METHOD OF REDUCING ABETA42 AND TREATING DISEASES BACE1, BACE2, APP PTGS1 1377/4885MEN1 1816/4885CYP2D6 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.